Tempest Therapeutics Reports Third Quarter 2026 Financial Results

News related to:Tempest Therapeutics · 3 min read

BRISBANE, Calif., Nov. 13, 2026 /CourierPR/ -- Tempest Therapeutics, a clinical-stage biotechnology company developing advanced in vivo CAR-T therapies for cancer and autoimmune diseases, reported financial results for the quarter ended September 30, 2026, and provided a business update. The company secured access to additional capital through an equity line of credit with Lincoln Park Capital Fund, LLC, allowing it to sell up to $50.0 million of its common stock, with an initial sale of 350,000 shares generating approximately $0.3 million in gross proceeds.

Tempest also strengthened its Board of Directors by appointing Nancy Freda-Smith and John W. Frederick, bringing valuable corporate governance and capital markets expertise. The company secured an exclusive license to develop and commercialize Senlang’s CD7-targeted lentiviral vector platform and associated in vivo CAR-T candidates worldwide, excluding China, with the lead program, TPST-4903, a BCMA/GPRC5D dual-targeting in vivo CAR-T candidate. TPST-4903 is being evaluated in a Phase 1 dose-escalation study for relapsed or refractory multiple myeloma (rrMM), with initial data expected to be presented at an upcoming scientific conference.

In addition, Tempest unveiled its next-generation in vivo CAR-T pipeline, including the lead product candidate TPST-4003, a dual-targeting CD19/BCMA in vivo CAR-T candidate. TPST-4003 combines the company’s proprietary CD7-targeted mRNA/LNP delivery with its clinically validated dual-target CAR architecture for broad B-cell lineage depletion and reset. An investigator-initiated trial in China evaluating TPST-4003 in approximately 10 patients with myasthenia gravis or multiple sclerosis is expected to begin in the fourth quarter of 2026.

Financially, Tempest ended the quarter with $0.9 million in cash and cash equivalents, down from $7.7 million on December 31, 2025. The decrease was primarily due to cash used in operations, including one-time transaction-associated costs incurred prior to or upon closing of the Asset Acquisition in February 2026, offset by the net proceeds from the company’s private placement of common stock and warrants in March 2026 of $1.7 million, the warrant inducement in May 2026 of $1.7 million, sales of common stock under the Lincoln Park equity line of credit of $0.3 million, and the company’s private placement in September 2026 of $1.8 million.

The company’s net loss for the quarter was $3.6 million, with a net loss per share of $0.21, compared to a net loss of $3.5 million and a net loss per share of $0.79 for the same period in 2025. Research and development expenses for the quarter were $0.2 million, down from $0.6 million for the same period in 2025, reflecting a decrease in costs due to portfolio re-prioritization after the Asset Acquisition in February 2026. General and administrative expenses for the quarter were $2.6 million, down from $3.0 million for the same period in 2025, primarily due to a decrease in one-time separation and other costs incurred in the third quarter of 2025.

For the nine months ended September 30, 2026, Tempest reported a net loss of $36.6 million, with a net loss per share of $2.54, compared to a net loss of $22.2 million and a net loss per share of $5.71 for the same period in 2025. Research and development expenses for the nine months were $2.1 million, down from $12.1 million for the same period in 2025, reflecting a decrease in costs due to re-prioritizing efforts towards exploring strategic alternatives initiated in April 2025 and resulting in the Asset Acquisition completed in February 2026. General and administrative expenses for the nine months were $11.5 million, up from $10.4 million for the same period in 2025, primarily due to one-time costs resulting from the Asset Acquisition completed in February 2026. Acquired in-process research and development expenses for the nine months were $22.2 million, compared to nil for the same period in 2025.

Start filing today

One press release free every week. No card required.

Create a free account